Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.

Tetsu HayashidaHiromitsu JinnoKatsuaki MoriHiroki SatoAkira MatsuiTakashi SakuraiHiroaki HattoriShin TakayamaMasahiro WadaMaiko TakahashiHirohito SekiTomoko SekiAiko NagayamaAkiko MatsumotoYuko Kitagawa

Published in: BMC cancer (2018)

This trial was retrospectively registered at the University Hospital Medical Information Network (UMIN) Clinical Trial Registry (ID number: UMIN000010334 ). Date of trial registration: April 1st, 2013.

Keyphrases

phase ii
clinical trial
metastatic breast cancer
phase iii
study protocol
open label
double blind
healthcare
randomized controlled trial
placebo controlled
social media
smoking cessation